Want to see HK:1498 full AI Analyst Report?
1498 Stock Chart & Stats
HK$0.35
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.35
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.27 - HK$0.49
Previous CloseN/A
Volume23.50K
Average Volume (3M)128.80K
Market Cap
HK$149.78M
Enterprise ValueHK$494.70
Total Cash (Recent Filing)HK$21.18M
Total Debt (Recent Filing)HK$351.14M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding535,897,640
10 Day Avg. Volume96,100
30 Day Avg. Volume128,800
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.14
Price to Sales (P/S)0.44
P/FCF Ratio5.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross MarginsGross margins near 53% indicate durable product-level profitability and likely pricing power or favorable product mix. High gross margins provide a consistent cushion to absorb SG&A or R&D spend, support cash conversion, and improve the company's ability to reinvest for sustainable growth over the medium term.
Cash GenerationPositive operating and free cash flow across 2022–2025 shows the business can internally generate liquidity even while reporting accounting losses. That capacity supports working capital, debt servicing, and targeted investments without sole reliance on external financing, improving medium-term resilience and execution options.
Improving Loss TrajectoryThe company has reduced the severity of prior losses versus the very weak 2022–2023 levels, signaling operational or mix improvements. A sustained narrowing of losses provides a foundation for management to achieve breakeven and eventual profitability if revenue stabilizes, making this a durable positive trend.
Bears Say
Persistent Net LossesContinuous EBIT and net losses over multiple years demonstrate structural unprofitability. Persistent below-the-line losses erode equity, constrain reinvestment and dividend capacity, and mean the company must convert operational improvements into sustained positive operating profit to restore long-term financial health.
Revenue ContractionA multi-year shrinking top line, including a -12% growth metric, weakens operating leverage and makes margin recovery harder. Structural revenue decline raises the bar for management actions, increasing dependence on market-share gains or successful new products to re-establish growth and durable profitability.
Elevated LeverageHigh and rising debt-to-equity (around 2.7x) combined with negative ROE indicates a weakened capital base and higher financial risk. With ongoing losses, elevated leverage increases refinancing and interest burden risks, reduces strategic flexibility, and heightens the chance that adverse shocks could impair solvency over the medium term.
PuraPharm Corp. Ltd. News
1498 FAQ
What was PuraPharm Corp. Ltd.’s price range in the past 12 months?
PuraPharm Corp. Ltd. lowest stock price was HK$0.27 and its highest was HK$0.48 in the past 12 months.
What is PuraPharm Corp. Ltd.’s market cap?
PuraPharm Corp. Ltd.’s market cap is HK$149.78M.
When is PuraPharm Corp. Ltd.’s upcoming earnings report date?
PuraPharm Corp. Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 16 days.
How were PuraPharm Corp. Ltd.’s earnings last quarter?
PuraPharm Corp. Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is PuraPharm Corp. Ltd. overvalued?
According to Wall Street analysts PuraPharm Corp. Ltd.’s price is currently Overvalued.
Does PuraPharm Corp. Ltd. pay dividends?
PuraPharm Corp. Ltd. pays a Annually dividend of HK$0.019 which represents an annual dividend yield of N/A. See more information on PuraPharm Corp. Ltd. dividends here
What is PuraPharm Corp. Ltd.’s EPS estimate?
PuraPharm Corp. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PuraPharm Corp. Ltd. have?
PuraPharm Corp. Ltd. has 535,897,640 shares outstanding.
What happened to PuraPharm Corp. Ltd.’s price movement after its last earnings report?
PuraPharm Corp. Ltd. reported an EPS of -HK$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PuraPharm Corp. Ltd.?
Currently, no hedge funds are holding shares in HK:1498
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PuraPharm Corp. Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.07%
Trailing 12-Months
Company Description
PuraPharm Corp. Ltd.
PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Mainland China, and international markets. Its operations are structured into five key divisions: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers a range of over-the-counter health solutions under brand names such as PuraGold, Haveron, Oncozac, and Immuzac. Beyond product sales, PuraPharm provides a clinic management system for general Chinese medical practices and operates its own chain of Nong's Chinese medicine clinics, which deliver both traditional medical services and CCMG products. The company also oversees the cultivation and trade of raw Chinese herbs, in addition to manufacturing and selling traditional Chinese medicine decoction pieces. Complementing its product offerings, it delivers modernized Chinese medicine services and diagnostic consultations. PuraPharm distributes its goods to hospitals, healthcare institutions, medical professionals, and directly to consumers via an online store. The company currently manages 43 Nong's clinics in Hong Kong and one in Guangxi, China. Founded in 1998, its headquarters are located in Tai Po, Hong Kong.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
Pak Fah Yeow International Limited
―
Golden Throat Holdings Group Co Ltd
―